← Leaderboards
Allison Payne
Utah State Higher Education System--University Of Utah
$5,406,882
Attributed
$6,574,746
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,574,746 · 4
By mechanism
R37$3,690,544 · 1
R01$2,335,729 · 1
R21$395,973 · 1
R03$152,500 · 1
Top collaborators
- Sarang Joshi4 shared
Most similar at Utah State Higher Education System--University Of Utah
Same institution · by research overlap
- Jindrich N. Kopecek$15,322,903
- Tracy Onega$9,327,018
- Sarang Joshi$4,391,146
- Henrik Carl Axel Odeen$1,385,825
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorFocused UltrasoundMagnetic ResonanceImageMonitorHistopathologyMagnetic Resonance ImagingEnvironmentClinical TrialsBreast Cancer TreatmentBreast Cancer PatientMalignant Breast NeoplasmIn VivoMinimally InvasiveThermometryValidationSafetyTissuesAblationTranslationsInnovationEnsureBreast Cancer TherapyCollaborations
Grant awards (15)
A tissue viability imaging biomarker for use in non-invasive breast cancer therapy$611,002
R01 · FY2025 · CA · contact PI
Quantitative evaluation of focused ultrasound thermal therapy on immunogenic cell death in breast cancer$215,985
R21 · FY2025 · CA · contact PI
A tissue viability imaging biomarker for use in non-invasive breast cancer therapy$555,975
R01 · FY2024 · CA · contact PI
Validation and translation of a non-invasive, MR-guided breast cancer therapy$506,060
R37 · FY2024 · CA · contact PI
Quantitative evaluation of focused ultrasound thermal therapy on immunogenic cell death in breast cancer$179,988
R21 · FY2024 · CA · contact PI
A tissue viability imaging biomarker for use in non-invasive breast cancer therapy$624,068
R01 · FY2023 · CA · contact PI
Validation and translation of a non-invasive, MR-guided breast cancer therapy$535,426
R37 · FY2023 · CA · contact PI
A tissue viability imaging biomarker for use in non-invasive breast cancer therapy$544,684
R01 · FY2022 · CA · contact PI
Validation and translation of a non-invasive, MR-guided breast cancer therapy$536,994
R37 · FY2022 · CA · contact PI
Validation and translation of a non-invasive, MR-guided breast cancer therapy$536,994
R37 · FY2021 · CA · contact PI
Validation and translation of a non-invasive, MR-guided breast cancer therapy$550,885
R37 · FY2020 · CA · contact PI
Validation and translation of a non-invasive, MR-guided breast cancer therapy$510,674
R37 · FY2019 · CA · contact PI
Quantitative assessment of MRgFUS with tissue-deformation corrected MRI-registered whole mount histology$76,250
R03 · FY2019 · EB · contact PI
Validation and translation of a non-invasive, MR-guided breast cancer therapy$513,511
R37 · FY2018 · CA · contact PI
Quantitative assessment of MRgFUS with tissue-deformation corrected MRI-registered whole mount histology$76,250
R03 · FY2018 · EB · contact PI